Your Health, We Care
The most common adverse reactions (≥ 20%) are edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite.
from FDA,2023.03
Capmatinib has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC) with mutations in MET exon 14, and its side effects are relatively manageable. The ···【more】
Article source：Lucius LaosRelease date：2024-11-11Recommended：232
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor activity, especially for the treatment of c-Met-dependent tumors.What are the side effects that can occ···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：221
Capmatinib is a MET inhibitor developed by Novartis specifically for patients with non-small cell lung cancer with specific gene mutations.What are the possible side effects when u···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：176
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, primarily for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutatio···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：194
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
